[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597586":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":57,"collaborators":30,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":30,"enrollmentInfo":69,"targetDuration":30,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":82,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","The placebo will be encapsulated to look identical to the study drug.",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Empagliflozin","OTHER","Matching 10-mg empagliflozin dose will be used.",[19],"Drug: Empagliflozin",[21,27],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Empagliflozin 10 mg, encapsulated to match the placebo, will be used.",[15],[26],"Jardiance",{"type":22,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"Matching placebo will be used.",[9],null,[32],{"name":33,"affiliation":34,"role":35},"Monique Cho, MD","VA Salt Lake City Health Care System, Salt Lake City, UT","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":30,"email":40},"CONTACT","(801) 582-1565","monique.cho@va.gov",[42],{"facility":34,"status":30,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Salt Lake City","Utah","84148-0001","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-111.89105,40.76078,{"lat":52,"lon":51},[55,56],{"name":33,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":33,"role":35,"phone":30,"phoneExt":30,"email":30},{"type":58,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100597586","phase-2-vascular-effects-of-sglt2i-in-non-diabetic-ckd-100597586",false,"NCT07060417","Vascular Effects of SGLT2i in Non-diabetic CKD","The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD","EMPA-CKD","Inclusion Criteria:\n\n* adults aged 18 years of age or older\n* eGFR 20-59 mL\u002Fmin\n* albuminuria \\\u003C300 mg\u002Fg\n\nExclusion Criteria:\n\n* Type 1 or 2 diabetes mellitus\n* expected to start dialysis or receive kidney transplantation or die within 4 months\n* prior therapy with SGLT2i within the previous year\n* unable to participate in the physical function tests (hand grip, walk)\n* infections requiring intravenous antibiotic treatment\n* malignancy requiring systemic therapy\n* extremity skin ulceration requiring active therapy\n* history of Fournier's gangrene\n* severe hypoglycemia requiring external assistance within the past one year\n* known allergy to empagliflozin\n* pregnancy","ALL","18 Years",{"count":70,"type":71},52,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage. The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.",[77],"Non-diabetic Chronic Kidney Disease",[79,80,81],"CKD","SGLT2 inhibitor","endothelial function","NOT_YET_RECRUITING","2026-05-26",{"date":85,"type":86},"2026-05-29","ACTUAL",{"date":88,"type":71},"2026-08-01",{"date":90,"type":71},"2029-09-30",{"name":5,"class":6},1]